The GLP-1 Patent Cliff: Why a Generic Arrives in Canada Before the United States
One patent family, filed 20 March 2006, expired on 20 March 2026 in countries applying a standard twenty-year term — India, China, Brazil, South Africa — and lapsed in Canada, which approved its first two generic semaglutide products in April and May 2026. In the United States, patent term extensions are expected to hold protection to at least 2032.
Why has the same patent expired in some countries and not others?
A patent is national. The same application, filed on the same day, produces rights that end on different dates depending on how each jurisdiction handles extensions. Semaglutide is the clearest live example in medicine right now.
| Market | Compound protection ends | Status as of 4 August 2026 |
|---|---|---|
| India, China, Brazil, South Africa | 20 March 2026 | Expired — generics in development |
| Canada | Lapsed — the national patent was allowed to lapse | First two generics approved April and May 2026 |
| European Union | March 2031, via supplementary protection certificates | Protected |
| Japan | approximately 2031 | Protected |
| United States | At least 2032 with term extensions | Protected |
Compiled 4 August 2026 from patent-law and industry analyses. Patent status changes with litigation; verify before relying on any date.
Three more patent families sit behind the compound patent
This is the part most coverage omits, and it is the reason a compound-patent expiry does not free the product.
- Method-of-use patents covering dosing and titration schedules, reported to run to 2032.
- Device patents on the pen injector mechanism, roughly 2029 to 2031.
- Formulation patents on SNAC, the absorption enhancer that lets an oral peptide survive the gut, to 2032.
Clearing one clears one. A generic manufacturer needs a path around all of them, or a licence.
Generic or biosimilar? The answer changes the economics
Semaglutide is a synthetic peptide, not a biologic. A copy therefore follows the ANDA generic pathway rather than the 351(k) biosimilar route. That matters commercially: a generic costs a fraction of a biosimilar to develop, which is why more than a dozen companies have signalled interest to the FDA. The first to file wins 180 days of exclusivity.
It does not shorten the patent wall. Cheap to develop and legal to sell are different questions.
Manufacturer self-pay figures read on the published price guide, 4 August 2026. Retail list is a third-party figure that very few people pay.
Can you import a foreign generic?
No. Importing an unapproved drug into the United States for personal use is unlawful, and a Health Canada or CDSCO approval is not an FDA approval. This is worth stating plainly because it is the obvious next thought after reading the table above.
It is also worth separating from compounding, which people conflate. A compounded preparation is not a generic. A generic is an approved copy demonstrated equivalent to the reference product. A compounded preparation has no such demonstration and no trial of its own.
What is actually moving American prices
Not the patent calendar. The manufacturer cut its US semaglutide list price substantially in January 2026 and opened direct self-pay channels; an approved oral tablet now starts at $149 a month. Those moves have changed what an American pays far more, and far sooner, than a 2032 expiry will on the day it arrives.
Plan around the routes that exist. Waiting six years for a price that may arrive gradually is not a plan.
Who is actually building generic semaglutide?
More than a dozen companies have signalled interest to the FDA, and the first to file a complete application wins 180 days of exclusivity as the sole generic on the US market. That prize is why development is running years ahead of the expiry date.
Outside the United States the activity is already commercial. Indian manufacturers have publicly planned launches, with industry estimates of dozens of brands entering that market. Canadian approvals arrived in April and May 2026. And Novo Nordisk has litigated to defend its position, including an action in the Delhi High Court in May 2026 — a reminder that an expired compound patent is the start of a legal contest, not the end of one.
| Step | What it requires | Typical timing |
|---|---|---|
| Compound patent expires | Nothing — it is a date | Fixed |
| Secondary patents cleared or designed around | Formulation, device, method-of-use | Often years |
| ANDA filed and accepted | Bioequivalence data | 12–24 months |
| First-to-file exclusivity | 180 days as sole generic | 6 months |
| Meaningful price competition | Several generics on market | Frequently 2–4 years after first approval |
This is why 'patent expires 2032' and 'prices fall in 2032' are different statements.
What a generic would realistically cost
Analysts modelling the US market have suggested a first entrant might price at a modest discount to brand rather than the 80–90% falls seen with small-molecule generics, because peptide manufacturing is capital-intensive and the initial field is narrow. Deep discounting arrives with the fourth and fifth entrant, not the first.
Set against that: an approved oral tablet already starts at $149 a month today, and brand self-pay is $349. A reader waiting for 2032 is waiting for a price that may not beat what is already available.
What this means for compounded programmes
A common argument holds that compounded preparations bridge the gap until a generic arrives. Two things complicate it. The compounding pathway narrowed sharply when the shortages were declared resolved, so the bridge is narrower than it was. And the approved-product price fell while the bridge narrowed, so the gap being bridged is smaller.
Neither point makes compounding illegitimate where a prescriber documents a clinical reason. Both change the arithmetic that made it the default answer to a cost question.
What we will be watching
- Whether US secondary patents are challenged, and how those challenges resolve. That, not the 2032 date, sets the real timeline.
- Canadian and Indian pricing, as a signal of where competitive pricing settles.
- Whether the oral formulation follows a different curve — its absorption-enhancer patent runs separately, so a generic tablet is not the same event as a generic injection.
How to read any "generic is coming" headline
Coverage of this topic collapses several separate questions into one date. Four checks separate a useful article from a misleading one.
- Which country? The same patent expired in March 2026 in four markets and runs to at least 2032 in the United States. A headline without a jurisdiction is not saying anything.
- Which patent? Compound, method-of-use, device and formulation patents expire on different dates. Clearing the compound patent is the first step, not the last.
- Which formulation? The injection and the oral tablet have separate patent estates. A generic tablet and a generic pen are different events.
- Approval or availability? First approval and meaningful price competition are frequently years apart.
What this analysis does not settle
- Whether US secondary patents survive challenge. That determines the real date more than the headline expiry does, and it is being litigated.
- What a US generic will cost. Peptide manufacturing economics differ from small-molecule generics, and first-entrant pricing is usually a modest discount.
- Whether approved-product prices keep falling. They have moved substantially in eighteen months, and that has changed what people pay far more than the patent calendar has.
Every date on this page was compiled on 4 August 2026 from patent-law and industry analyses. Patent status changes with litigation and settlement; verify before relying on any of it.